Jeffrey Alan Jones - Feb 28, 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Medical Officer
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
4
Date filed
3/2/2022, 06:05 PM
Next filing
Feb 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +215K $0.00 215K Feb 28, 2022 Common Stock 215K $14.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option represents a right to purchase a total of 215,000 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on February 28, 2023, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.